Contents

August 2011 • Volume 5 Number 3

3 Editorial comment
Tracy Crooks

4 Risks of off-label medicines in children
One fifth of all spontaneous ADRs reported in Danish children were associated with off-label prescribing and 60% were serious.
Lise Aagaard and Ebba Holme Hansen

8 Electronic submission of ADRs
The Yellow Card scheme for hospital medical information centres has been expanded for use by the pharma industry to enable it to transfer data electronically.
Keith Brown and Steve Moss

11 Preparing for Development Safety Update Reports: some implications for pharmaceutical companies
From September 2011 companies sponsoring clinical trials in the EU should submit Development Safety Update Reports (DSURs). This article summarises the guidelines and implications.
Dr Elliot Brown

17 UK Inspection findings for 2010/2011
The latest MHRA Pharmacovigilance Inspection Reports for 2011/2011 show a continuation of the steady decrease in the number of fundings per inspection.
Joe Ridge

20 Detecting drug interactions from adverse-event reports
Data mining of the FDA’s Adverse Events Reporting System has proved to be a useful method of detecting potentially important clinical signals.
Ros Manning